Evidence map›Paper›PMID 38114258›Full record

ArticleCMAJ open

The success of publicly funded rotavirus vaccine programs for preventing community- and hospital-acquired rotavirus infections in Canadian pediatric hospitals: an observational study.

Nicole Le Saux, Julie Bettinger, Hennady P Shulha, Manish Sadarangani, Doug Coyle, Timothy F Booth, Taj Jadavji, Scott A Halperin, For members of Immunization Monitoring Program Active

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CMAJ open. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Nicole Le SauxChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS lesaux@cheo.on.ca.
Julie BettingerChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Hennady P ShulhaChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Manish SadaranganiChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Doug CoyleChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Timothy F BoothChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Taj JadavjiChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
Scott A HalperinChildren's Hospital of Eastern Ontario (CHEO) (Le Saux), University of Ottawa, Ottawa, Ont.; Vaccine Evaluation Center, BC Children's Hospital Research Institute (Bettinger, Shulha, Sadarangani), University of British Columbia, Vancouver, BC; School of Epidemiology and Public Health (Coyle), University of Ottawa, Ottawa, Ont.; Viral Diseases Division, National Microbiology Laboratory (Booth), Public Health Agency of Canada, Winnipeg, Man.; Alberta Children's Hospital (Jadavji), University of Calgary, Alta.; Dalhousie University and Canadian Center for Vaccinology (Halperin), IWK Health Centre, Halifax, NS.
For members of Immunization Monitoring Program Active
University of British Columbia · CADalhousie University · CAIzaak Walton Killam Health Centre · CABC Children's Hospital · CAChildren's Hospital of Eastern Ontario · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCanadian immunization programs for rotavirus started in 2011. We sought to determine their effect on the burden of community-acquired admissions and hospital-acquired rotavirus at pediatric hospitals.

methodsThe Canadian Immunization Monitoring Program Active (IMPACT) network conducted active surveillance for rotavirus-positive hospital admissions between 2005 and 2020 at 12 pediatric hospitals. We used yearly rates of community-acquired rotavirus per 10 000 admissions and hospital-acquired rotavirus infections per 1000 patient-days to determine changes in the pre- and post-vaccine program periods.

resultsDuring the 15-year study period, 5691 rotavirus hospital admissions and hospital-acquired infections were detected, including 4323 (76%) community-acquired infections and 1368 (24%) hospital-acquired infections. The average community-acquired rate in the pre-vaccine period was 60.3 (95% confidence interval [CI] 53.7-68.3) per 10 000 admissions, with a decline to 11.0 (95% CI 7.5-15.1) per 10 000 admissions in the post-vaccine period, resulting in an average reduction of 81.7% (95% CI 74.4%-87.8%). The rate of hospital-acquired rotavirus declined from 0.35 (95% CI 0.29-0.41) per 1000 patient-days in the pre-vaccine period to 0.05 (95% CI 0.03-0.07) per 1000 patient-days in the post-vaccine period, resulting in an 85.3% (95% CI 77.7%-91.9%) average decline. Herd protection was present among children aged 2-16 years.

interpretationAlthough start dates of rotavirus vaccine programs across provinces varied, there was around an 80% average decrease in both community-acquired and hospital-acquired rotavirus infections at pediatric hospitals in Canada in the 1- to 9-year interval after implementation of rotavirus vaccine programs. Herd protection is an important aspect of rotavirus vaccines for other children who are not vaccine eligible, and rotavirus vaccines continue to provide important benefits both for children and health care systems.

Identifiers

PMID38114258
PMCPMC10743644
OpenAlexW4390015986

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.